Replies to post #9945 on Titan Pharmaceuticals Inc (TTNP)

[Doctor Detroit]

I think there is something to that. Especially when, if management is asked a question about probuphine on a conference call (sales estimates, timing of chronic pain supplemental NDA), they have to admit that they don't know.

Which is why many of us are so frustrated of the lack of progress over matters where management is calling the shots: development of the Pro Neura platform and a ROW partnership.

A convincing "story" for management to tell is they have a great Pro Neura platform (T3, Parkinsons and other indications) that can be funded without further dilution by using probuphine royalties and milestones. But they have to show execution on that platform.

[Rentier]

Won't matter once earnings start rolling in the market will have to react and honor the P/E ratio.